Transaction DateRecipientSharesTypePriceValue
1st January 2021Seymour Liebman34,188Exercise of derivative$0.00
1st January 2021David B Elsbree34,188Exercise of derivative$0.00
4th December 2020Sachs Group Inc Goldman775,000Bona fide gift$0.00
30th November 2020Sachs Group Inc Goldman2,060,000Bona fide gift$0.00
13th November 2020Sachs Group Inc Goldman2,129,000Bona fide gift$0.00
12th November 2020Sachs Group Inc Goldman1,401,879Other acquisition or disposition$50.09$70,220,119.11
28th September 2020Sachs Group Inc Goldman1,860Exercise of in-the-money or at-the-money derivatives securities (usually options)$0.00
22nd September 2020Sachs Group Inc Goldman1,013,165Open or private sale$19.00$19,250,135.00
17th August 2020Sachs Group Inc Goldman1,500,000Open or private sale$27.50$41,250,000.00
17th August 2020Sachs Group Inc Goldman225,000Open or private sale$27.50$6,187,500.00
T2 Biosystems
T2 Biosystems logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 10/10.

T2 Biosystems, Inc. engages in the development of proprietary technology platform. It offers the T2 Magnetic Resonance technology which enables rapid detection of pathogens, biomarkers and other abnormalities.

Ticker: TTOO
Sector: Health Technology
Industry: Biotechnology
SEC Central Index Key (CIK): 1492674
Employees: 151
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags
Cash at Carrying Value: $27 M (0%)
Marketable Securities, Current: $9 M (0%)
Inventory, Net: $4 M (0%)
Assets, Current: $47 M (150%)
Property, Plant and Equipment, Net: $4 M (0%)
Other Assets, Noncurrent: $206 Th (0%)
Assets: $54 M (88%)
Accounts Payable, Current: $2 M (-52%)
Accrued Liabilities, Current: $6 M (0%)
Liabilities, Current: $8 M (-86%)
Common Stock, Value, Issued: $128 Th (150%)
Common Stock, Shares, Issued: $128 M (153%)
Additional Paid in Capital, Common Stock: $397 M (16%)
Retained Earnings (Accumulated Deficit): $402 M (0%)
Stockholders' Equity (Parent): $4 M (0%)
Liabilities and Equity: $54 M (88%)
Revenue: $3 M (0%)
Research and Development: $4 M (-55%)
Operating Income/Loss: $9 M (-60%)